Thrivent Financial for Lutherans
CPRX

Thrivent Financial for Lutherans’s Catalyst Pharmaceutical CPRX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37M Sell
75,542
-1,577
-2% -$46.5K ﹤0.01% 1419
2026
Q1 		$1.91M Sell
77,119
-2,270
-3% -$54.1K ﹤0.01% 1498
2025
Q4 		$1.85M Sell
79,389
-3,610
-4% -$80.4K ﹤0.01% 1543
2025
Q3 		$1.64M Sell
82,999
-1,310
-2% -$26.9K ﹤0.01% 1465
2025
Q2 		$1.83M Buy
84,309
+1,957
+2% +$46.2K ﹤0.01% 1412
2025
Q1 		$2M Sell
82,352
-4,308
-5% -$97K ﹤0.01% 1291
2024
Q4 		$1.81M Sell
86,660
-952
-1% -$20.5K ﹤0.01% 1506
2024
Q3 		$1.74M Sell
87,612
-5,538
-6% -$103K ﹤0.01% 1539
2024
Q2 		$1.44M Sell
93,150
-3,740
-4% -$58.2K ﹤0.01% 1615
2024
Q1 		$1.54M Buy
96,890
+7,591
+9% +$114K ﹤0.01% 1607
2023
Q4 		$1.5M Sell
89,299
-2,353
-3% -$32.2K ﹤0.01% 1581
2023
Q3 		$1.07M Sell
91,652
-1,618
-2% -$21.6K ﹤0.01% 1694
2023
Q2 		$1.25M Sell
93,270
-1,615
-2% -$23.2K ﹤0.01% 1656
2023
Q1 		$1.57M Sell
94,885
-3,326
-3% -$54.9K ﹤0.01% 1466
2022
Q4 		$1.83M Buy
98,211
+427
+0.4% +$6.57K ﹤0.01% 1312
2022
Q3 		$1.25M Buy
+97,784
New +$1.16M ﹤0.01% 1523

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Thrivent Financial for Lutherans's CPRX Position: Q2 2026 in Review

Thrivent Financial for Lutherans reduced its Catalyst Pharmaceutical (CPRX) stake by 2% in Q2 2026, selling an estimated $46.5K and leaving 75,542 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1419.

Thrivent Financial for Lutherans first reported a position in CPRX in Q3 2022 and has held it in 16 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Thrivent Financial for Lutherans held 75,542 shares of Catalyst Pharmaceutical worth $2.37M as of Q2 2026.
  • Thrivent Financial for Lutherans sold 1,577 Catalyst Pharmaceutical shares in Q2 2026, an estimated $46.5K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #1419 holding.
  • Thrivent Financial for Lutherans first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.